TD Cowen Reiterates Buy Rating on Humacyte (HUMA)

TD Cowen analyst Joshua Jennings reiterated a Buy rating and $10.00 price target on Humacyte (NASDAQ: HUMA).

The analyst commented, "HUMA shares were under pressure after Form 483 observations from the FDA manufacturing facility inspection were made public. We assume the company resolved the minor items months ago. Although we haven't been in contact with management, we do not believe these observations remain outstanding and are not the root cause of the delay in the BLA approval decision."

For an analyst ratings summary and ratings history on Humacyte click here. For more ratings news on Humacyte click here.

Shares of Humacyte closed at $4.86 yesterday.

You May Also Be Interested In

• Wells Fargo Upgrades Invitation Homes (INVH) to Overweight
• H.C. Wainwright Reiterates Buy Rating on Climb Bio (CLYM)
• Tenax Therapeutics (TENX) Reiterated at Overweight by Cantor Fitzgerald: Ph3 Data in Q3